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Abstract
Background:  There are around 350 million of hepatitis B surface antigen (HBsAg) carriers
worldwide, and among them, high risk of developing hepatocellular carcinoma (HCC) has been
identified by epidemiological studies. To date, the molecular role of HBsAg in HCC development
has not been fully studied. We have previously reported that in cell cultures, HBsAg up-regulated
the expression of lymphoid enhancer-binding factor 1 (LEF-1), a key component of the Wnt
pathway. In this study we aimed to study this effect of HBsAg on LEF-1 in the development of HCC.
Methods: Expression of HBsAg, LEF-1 and its downstream effector genes were compared among
30 HCCs, their peritumor tissue counterparts and 9 normal control liver tissues by quantitative
real-time PCR. In addition, immunohistochemical staining studies on HBsAg and LEF-1 expression
were conducted among these samples.
Results: The expression of LEF-1 was compared between 13 HBsAg positive HCC tissues and 17
HBsAg negative HCC tissues. Simultaneous detection of LEF-1 and HBsAg was observed in HBsAg
positive HCC tissues and, additionally, the simultaneous detection of HBsAg and LEF-1 was more
pronounced in peritumor tissues, compared to that in the tumor tissues. The distribution of
cellular LEF-1 in peritumor tissues was predominantly in the cytoplasm; while LEF-1 in the tumor
tissues was located either exclusively in the nucleus or both in the nucleus and cytoplasm. By real-
time PCR, the expression levels of LEF-1 downstream effector genes cyclin D1 and c-myc were
higher in peritumor cells compared to that of the tumor cells. However, a 38 kDa truncated
isoform of LEF-1, rather than the 55 kDa wild-type LEF-1, was significantly elevated in the HBsAg
positive tumor cells.
Conclusion: Data indicate that deregulation of the Wnt pathway by HBsAg occurred in HBV-
associated HCCs, but was more pronounced in the peritumor cells. It is speculated that HBsAg
could stimulate proliferation and functional modification of hepatocytes via LEF-1 through the Wnt
pathway at the pre-malignant stage.
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Background
Hepatitis B virus (HBV) is the prototype of hepadnaviridae.
It is estimated that around 350 million people are carriers
of hepatitis B surface antigen (HBsAg) worldwide [1,2].
Persistent HBV infection leads to chronic hepatitis, and is
closely associated with the development of liver cirrhosis
and hepatocellular carcinoma (HCC) [3]. Three forms of
viral particles can be detected in the serum of HBV
infected patients, namely, 42 nm diameter mature virion
particles, 22 nm diameter spherical particles and 22 nm
diameter filamentous particles [4]. Uniquely, 22 nm sub-
viral particles, which are composed of HBsAg and do not
contain viral DNA, usually outnumber the virions in
patient serum by a factor of 1000-fold or more [5].
Though HBsAg has been identified as the neutralizing
antigen of HBV and has been used as the major compo-
nent of preventive vaccine for viral hepatitis B, persistence
of HBsAg in serum of patients has been recognized as a
high risk factor for development of HCC [6,7]. The possi-
ble roles of HBV envelope proteins LHBs (Pre-S1/Pre-S2/
S) and MHBs (Pre-S2/S) in HCC development have been
reported [8,9]. However, the role of major HBsAg in tum-
origenesis has not been studied in detail.
By microarray study of cells transfected with the S gene
coding for HBsAg, we have previously shown that marked
up-regulation of lymphoid enhancer-binding factor 1
(LEF-1), a transcriptional factor in Wnt  pathway, was
closely correlated with HBsAg expression [10]. Further-
more, the expression level and cellular distribution of
LEF-1 protein, mainly the dominant negative truncated
isoform, was changed by the expression of HBsAg. In this
study, we aimed to investigate the roles played by HBsAg
on LEF-1 expression in the development of HBV-associ-
ated HCC. By immunohistochemical analysis and molec-
ular studies, the intracellular expression and distribution
of LEF-1 and HBsAg, cyclin D1 and c-myc gene expression
were compared between HBsAg positive and negative
HCC tissues, peritumor tissues and normal liver tissues.
The possible roles of HBsAg in HCC development are dis-
cussed.
Methods
Human liver tissues
Thirty surgical resected HCC tissues from different indi-
viduals were provided by Shanghai Cancer Institute. Tis-
sue samples were categorized as tumorous (T) or matched
adjacent peritumorous liver tissues (pT) by hematoxylin
and eosin (HE) stained sections under the microscope.
The size and regions of the resection of the tumorous and
peritumorous tissues were decided by the surgeons based
on each individual case under the regulation of the ethics
committee. All these HCCs were associated with HBV
infection as defined by serum HBsAg positive. Normal
liver tissues (NL) from liver transplantation donors (n =
9) were obtained from Shanghai Cancer Institute and First
Affiliated Hospital, Zhejiang University School of Medi-
cine (kindly provided by Dr. Shusen Zheng). All samples
collected followed the regulations of the ethics commit-
tees of both hospitals.
Immunohistochemical staining
Resected liver tissue samples were immediately immersed
in 4% formalin and fixed for 18 to 24 h and paraffin-
embedded. Immunohistochemical staining was carried
out on tissue sections by using anti-LEF-1 polyclonal rab-
bit antibody (1:50, Abcam, Cambridge, UK) or anti-
HBsAg monoclonal antibody (1:50, Changdao Biotech,
Shanghai, China) to detect the expression of LEF-1 and
HBsAg respectively.
Reverse transcription and real-time PCR
After treated with 10 U DNase I (TaKaRa, Dalian, China)
at 37°C for 30 min, 2 μg total RNA was reverse transcribed
into cDNA by SuperScript II reverse transcriptase (Invitro-
gen, Carisbad CA, USA) according to the manufacturer's
protocol. Quantitative real-time PCR was carried out
using specific primer pairs designed by PrimerBank [11].
For real-time PCR, 2 μl of 10-fold dilutions of the cDNA
products were assayed using the Premix Ex Taq Perfect
Real Time PCR kit (TaKaRa, Dalian, China). To assess the
association of HBsAg and LEF-1 isoforms in HCC tissues,
two pairs of primers were designed to detect different LEF-
1 isoforms. Primers LP1 and LP2 were designed to target
the β-catenin binding domain, which could differentiate
the 38 kDa truncated LEF-1 isoform from the 55 kDa full-
length LEF-1 [12]. Another pair of primers LP3 and LP4
was targeted to the 3' UTR region of LEF-1 mRNA, and
thus could detect both the full length and the isoforms.
The house keeping gene GAPDH was used as an internal
control. All experiments were performed twice independ-
ently. Primers used in this study are listed in Table 1.
Statistical analysis
The Wilcoxon signed rank tests were performed to evalu-
ate the difference of expression levels of LEF-1, cyclin D1
and c-myc between HCC tissues and normal tissues. Tests
were considered of statistical significance when their p val-
ues were less than 0.05.
Results
Expression and distribution of HBsAg and LEF-1 protein in 
HCC tissues
Immunohistochemical staining of the HCC tissues
showed that HBsAg was detected in 13 of 30 HCC tissues,
either in tumor cells or peritumor cells. HBsAg was
detected only in 5 out of the 13 tumor tissues, while in the
paired peritumor tissues, HBsAg was observed in all 13
samples (Table 2). LEF-1 was detected in both tumor cells
and peritumor cells of all 30 HCC tissues, with no signif-Journal of Experimental & Clinical Cancer Research 2009, 28:58 http://www.jeccr.com/content/28/1/58
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icant difference between tumor cells and peritumor cells.
When LEF-1 expression level was analyzed in the HBsAg
positive tissues, it was simultaneously associated with the
expression levels of HBsAg (Figure 1 and Table 2). The exs-
pression of LEF-1 was found more pronounced in peritu-
mor tissues, compared to that in the tumor tissues among
HBsAg positive HCC samples, whereas, no significant dif-
ferences of LEF-1 expression were observed between
tumor cells and peritumor cells in the other 17 HBsAg
negative tissues. Cellular distribution pattern of LEF-1
protein was compared between peritumor cells and tumor
cells of HBsAg positive tissues. LEF-1 protein was located
either exclusively in the nucleus or both in the nucleus
and cytoplasm of tumor cells, whereas in peritumor cells
LEF-1 was located predominantly in the cytoplasm (Fig-
ure 2 and Table 2). When the expression of LEF-1 protein
was compared with that of HBV negative normal liver tis-
sues, marked up-regulation of LEF-1 was observed both in
tumor tissues and the peri-tumor tisseus among all of 30
HCC tissues. The cellular location of LEF-1 in normal liver
cells was in the cytoplasm, more closely representing that
in peritumor cells (Figure 2).
Table 1: Primers of real-time PCR in this study
Gene Primers
GAPDH Forward: GGTATCGTGGAAGGACTCATGAC
Reverse: ATGCCAGTGAGCTTCCCGTTCAG
LEF-1-full length (LP1 and LP2) Forward: AATCATCCCGGCCAGCA
Reverse: TGTCGTGGTAGGGCTCCTC
LEF-1-isoform (LP3 and LP4) Forward: CATAGTGGCTTCTCCGCCCTTGTAAG
Reverse: TTCAAGTGCTGGGCTTTTTACAACAAG
cyclin D1 Forward: GCTGGAGCCCGTGAAAAAGA
Reverse: CTCCGCCTCTGGCATTTTG
c-myc Forward: CTGTATGTGGACGGCTTCTCG
Reverse: CTGCTGTCGTTGAGAGGGTAG
Correlation between HBsAg and LEF-1 expression levels in HCC tissues Figure 1
Correlation between HBsAg and LEF-1 expression levels in HCC tissues. Expression levels of HBsAg (A) and LEF-1 
(B) were analyzed by the immunohistochemical studies in 13 HBsAg positive HCC tissues. LEF-1 expression was positively cor-
related with HBsAg expression. The units of expression levels were set arbitrarily which were defined according to the color 
density by immunohistochemical staining. The examples of arbitrary units of color density are shown (1 faint brown, 2 median 
brown, 3 brown, 4 dark brown).Journal of Experimental & Clinical Cancer Research 2009, 28:58 http://www.jeccr.com/content/28/1/58
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Intracellular expression and distribution of HBsAg and LEF-1 in liver tissue sections Figure 2
Intracellular expression and distribution of HBsAg and LEF-1 in liver tissue sections. HBsAg (A, C, E) and LEF-1 
protein (B, D, F) expression in liver tissues sections was determined by immunohistochemical staining using anti-HBsAg mono-
clonal antibody and anti-LEF-1 rabbit polyclonal antibody respectively (400× magnification). HBsAg and LEF-1 expression and 
cellular distribution were studied and compared in tumor tissues (T) (A, B), peritumor tissues (pT) (C, D) and normal liver tis-
sues (NL) (E, F). As shown, HBsAg was expressed at lower level in tumor tissues compared to that of peritumor tissues, and 
LEF-1 was found exclusively in the nucleus in tumor tissues, whereas it was mainly detected in the cytoplasm in peritumor tis-
sues.Journal of Experimental & Clinical Cancer Research 2009, 28:58 http://www.jeccr.com/content/28/1/58
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Deregulation of LEF-1 isoforms in HCC tissues
The expression pattern of LEF-1 isoforms was studied in
HCC tissues by quantitative real-time PCR. Results
showed that compared to that of normal liver tissues by
real-time PCR, both 38 kDa truncated isoform and 55 kDa
full-length LEF-1 were markedly increased in tumor cells
and peritumor cells (Figure 3). However, when compared
to that in the peritumor cells, the 38 kDa truncated iso-
form of LEF-1 was more markedly induced in tumor cells,
(Figure 3A), while the 55 kDa full-length LEF-1 did not
show significant changes (Figure 3B). To further investi-
gate the association of the expression pattern of LEF-1 iso-
forms and HBsAg expression, LEF-1 isoforms were
analyzed in 13 HBsAg positive HCC tissues. The 38 kDa
truncated isoform of LEF-1 was significantly up-regulated
in tumor cells compared to that in the peritumor cells,
while the 55 kDa full-length LEF-1 did not exhibit changes
between tumor and peritumor cells (Table 2). However in
the other 17 HBsAg negative HCC tissues, no significant
changes were observed in either isoforms.
Up-regulation of downstream target genes of Wnt 
pathway
To further study the deregulation of Wnt pathway induced
by aberrant up-regulation of LEF-1, expression levels of c-
myc and cyclin D1 in HCC tissues and normal liver tissues
were compared by real-time PCR. Results showed that
compared to that of normal livers, the expression of cyclin
D1 and c-myc was increased significantly in both tumor
cells and peritumor cells of HCC tissues (Figure 4). In
addition, the expression level of cyclin D1 was much
higher in peritumor cells compared to that of tumor cells,
and c-myc expression showed a similar pattern (Figure 4).
Discussion
Hepatocellular carcinoma is the fifth most common
malignancy worldwide [13]. Its risk factors include
chronic infections by hepatitis B and C virus (HBV and
HCV), and nonviral liver diseases [14,15]. Epidemiologi-
cal study indicated that long term persistence of HBsAg in
chronic hepatitis B patients is a risk factor for the develop-
ment of HCC [7]. Extensive studies have been carried out
Table 2: The expression pattern and intracellular distribution of HBsAg and LEF-1 in 13 HBsAg positive HCC tissues.
Peritumor Tissue (%) Tumor Tissue (%) P value
HBsAg expression 13/13 (100) 5/13 (38.5)
LEF-1 intracelluler location Nucleus 4/13 (30.8) 9/13 (69.2)
Cytoplasm 7/13 (53.8) 0/13 (0)
Cytoplasm & Nucleus 2/13 (15.3) 4/13 (30.8)
LEF-1 isoforms abundance* 38 kDa LEF-1 2.69 ± 2.26E-03 2.34 ± 3.64E-02 0.03
55 kDa LEF-1 1.49 ± 2.30E-02 1.51 ± 1.90E-02 0.98
* Results are the arbitary units which represent the relative abundance of LEF-1 mRNA.
Expression levels of LEF-1 isoforms in HCC tissues Figure 3
Expression levels of LEF-1 isoforms in HCC tissues. 
By real-time PCR, the expression levels of 38 kDa truncated 
isoform of LEF-1 (A) and 55 kDa full-length LEF-1 (B) were 
compared in tumor tissues (T), peritumor tissues (pT) and 
normal liver tissues (NL). The value of the Y axis is the arbi-
trary unit which reflects the relative abundance of LEF-1. The 
GAPDH was used as an internal control of real-time PCR. 
The expression levels of LEF-1 isoforms were significantly 
induced in tumor tissues compared to that of peritumor tis-
sues and normal liver tissues (* p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:58 http://www.jeccr.com/content/28/1/58
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to reveal the roles of HBV in contributing to proliferation
and anti-apoptotic behavior of HCC cells [16,17]. Cumu-
lative data suggested that HBx is a multifunctional regula-
tory viral protein, which interferes directly or indirectly
with a variety of cellular functions including cell cycle pro-
gression, transformation and apoptosis [18-20]. Other
groups reported that LHBs and MHBs functioned as trans-
activators which induced cell proliferation and/or cell
death of hepatocytes [21-23]. In this study we investigated
the possible roles played by major HBs in tumorgenesis,
and the association between HBsAg expression and Wnt
signaling pathway deregulation in HBV-associated HCC
tissues.
To reveal the implications of in vivo association between
HBsAg and LEF-1 up-regulation in HCC, the expression
levels of these two proteins were compared both by
immunohistochemical staining and by real-time PCR
among HCC tumor tissues, peritumor tissues and normal
liver tissues. Experimental data have shown that the aber-
rant regulation of the canonical Wnt pathway was one of
the important events involved in HCC development
[24,25]. However, mutations in β-catenin or adenoma-
tous polyposis coli (APC) genes, which appeared in over
90% of colorectal cancers [26,27] were found only in
about 20–30% of HCCs [28], suggesting that the predom-
inant mechanisms activating Wnt signaling pathway in
HCCs could be different from that in other cancers. Ben-
gochea et al reported that deregulation of Wnt/Frizzled
receptor elements was common in human hepatocellular
carcinoma [29], and disturbance of regulatory mecha-
nisms other than mutations involving β-catenin is more
likely of importance in HCC. Our results on the molecular
expression levels among 30 HCC tissue and 9 normal liver
tissues showed that HBsAg up-regulated not only LEF-1
but also the two of LEF-1 downstream genes expression
levels. These finding provided evidence that HBsAg
affected the Wnt pathway via up-regulation of LEF-1.
In this study, though all 30 HCC samples were collected
from serum HBsAg positive patients, only 13 liver tissues
were HBsAg positive by immunohistochemical staining.
Since the expression pattern of LEF-1 was not significnatly
changed in HBsAg negative HCC tissues, to reveal the
roles of HBsAg on HCC development, we concentrated on
these 13 pairs of HBsAg positive samples. Specifically, the
expression levels of HBsAg, LEF-1, cyclin D1 and c-myc
were studied in tumor cells and peritumor cells from the
same patient. LEF-1 expression levels were found associ-
ated with the levels of HBsAg expression in HCC tissues.
Interestingly, the intracellular distribution of LEF-1 pro-
tein in tumor cells was different from that in peritumor
cells. In the peritumor cells LEF-1 was predominantly
located in the cytoplasm, while in the tumor cells LEF-1
was located exclusively in the nucleus or both in the
nucleus and cytoplasm. This observation is in accordance
with a recent report stating that LEF-1/TCF was up-regu-
lated in 52% of HCCs by strong nuclear LEF-1/TCF stain-
ing [30]. As we have previously observed that expression
of HBsAg initiated transfer of LEF-1 from the cytoplasm
into the nucleus, in this study, we further identified that
the transfer of LEF-1 into the nucleus also occurred in
tumor cells. The different distribution of LEF-1 in tumor
cells and peritumor cells suggests that different mecha-
nisms could be involved in the pre-malignant stage and
the malignant stage in HBV associated HCC.
Our previous study showed that the 38 kDa truncated iso-
form of LEF-1 was markedly induced in HBsAg expressing
Expression levels of cyclin D1 and c-myc in HCC tissues Figure 4
Expression levels of cyclin D1 and c-myc in HCC tis-
sues. By real-time PCR, the expression levels of LEF-1 
downstream effector genes cyclin D1 (A) and c-myc (B) were 
compared in tumor tissues (T), peritumor tissues (pT) and 
normal liver tissues (NL). The expression levels of cyclin D1 
and c-myc were significantly induced in tumor tissues com-
pared to that of peritumor tissues and normal liver tissues (* 
p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:58 http://www.jeccr.com/content/28/1/58
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cells, while full-length LEF-1 did not show a significant
change. It was reported that the 55 kDa full-length LEF-1
contains three functional domains, namely, β-catenin
binding domain, context-dependent activation domain
(CAD) and HMG DNA binding domain, while the 38 kDa
truncated isoform of LEF-1 which lacks the β-catanin
binding domain derived from an intronic promoter and
exhibits dominant negative activity [31,32]. To further
investigate the expression of LEF-1 isoforms in HCCs,
quantitative real-time PCR was employed to analyze the
expression patterns of LEF-1 isoforms in 30 pairs of HCC
tissues in tumor cells and peritumor cells. Compared to
those in normal liver tissues, though both isoforms were
significantly up-regulated in HCC, the 38 kDa truncated
isoform of LEF-1 was more significantly up-regulated in
tumor cells, than that in peritumor cells especially in
those 13 HBsAg positive HCC tissues. The 55 kDa full-
length LEF-1 showed no changes between tumor cells and
peritumor cells. This observation further suggested that
the molecular signaling cascades could have been
changed between peritumor cells and tumor cells.
To further confirm the association of LEF-1 and HBsAg,
expression pattern of LEF-1 in 13 HBsAg positive HCC tis-
sues was analyzed and compared to that in 17 HBsAg neg-
ative HCC tissues. The expression of LEF-1 was found
closely associated with the HBsAg expression in HBsAg
positive HCC tissues. However no significant differences
were observed either in LEF-1 protein or LEF-1 isoforms
when compared between tumor cells and peritumor cells
in these HBsAg negative tissues. The different expression
patterns of LEF-1 between HBsAg positive and negative
HCC tissues suggested that HBsAg could play important
roles in regulating Wnt signaling pathway, thus providing
new insights into the involvement of HBsAg in hepatocar-
cinogenesis. However, the molecular mechanisms of
HBsAg-LEF-1 interaction and their roles in the develop-
ment of HCC merit further investigation. Other viral or
cellular factors might also be involved in the interaction
between HBV and Wnt pathway. For instance, HBx has
been reported to be essential for the activation of Wnt/b-
catenin signalling in hepatoma cells [33], and reduced the
phosphorylation level of b-catenin by suppressing GSK-
3b function through the Erk pathway [34].
Cyclin D1 and c-myc are key regulatory genes in the control
of cell cycle and cell proliferation, and thus are the best-
known candidates among the LEF-1 regulated genes
[35,36]. Over-expression of cyclin D1 ranged from 5.6% to
54% of HCCs and was associated with advanced clinico-
pathological stage [30]. Up-regulation of c-myc gene was
reported by Kawate et al in 33% of HCCs by differential
PCR analysis [37]. However, to date, the roles of cyclin D1
and c-myc in HCCs are still not well defined. In this study,
expression of cyclin D1 and c-myc was markedly increased
in HCC tissues, compared with normal liver tissues but
the expression levels of these two genes were higher in
peritumor cells than that of tumor cells. This could partly
be attributed to the over-expression of 38 kDa dominant
negative LEF-1 isoform in tumor cells. Up-regulation of
38 kDa dominant negative isoform of LEF-1 in tumor cells
could suppress rather than activate the Wnt  pathway.
Therefore the downstream target genes, cyclin D1 and c-
myc, were induced at a lower level in the tumor cells, com-
pared to that of peritumor cells. However the complexity
of  cyclin D1 and c-myc  in HBV-associated HCC tissues
should be considered.
Conclusion
Taken together, as there was higher expression of HBsAg
in peritumor cells and higher up-regulation of LEF-1 in
the cytoplasm of cells, as well as higher up-regulation of
cyclin D1 and c-my, it is predicted that HBsAg exerted pro-
nounced effects on LEF-1 and its downstream genes in
hepatocytes, resulting in more active cell proliferation,
which could promote or enhance malignant transforma-
tion of hepatocytes by other viral or cellular mechanisms.
It is postulated that HBsAg interacted with liver cells only
at the pre-malignant stage, and thus plays the role of an
initiator during the process of HCC development.
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